This image will be automatically disabled when it gets reported by several people.
Minimally invasive treatment provides fast pain relief for cancer patients Patients with debilitating bone tumours experienced improved quality of life in as little as 3 days
A minimally invasive treatment for patients whose cancer has spread to their bones provides quick and sustained pain relief and improves quality of life. The new finding was discovered in a new study which will be presented at the Society of Interventional Radiology Annual Scientific Meeting. The palliative treatment, known as radiofrequency ablation (RFA), is effective in providing relief in as little as three days. In a bonus, the benefits last more than 12 months, providing a significant improvement over radiation treatment. "Commonly used radiation treatments can take weeks to provide pain relief," said Jason Levy MD, a vascular and interventional radiologist at Northside Hospital in Atlanta and lead researcher of the study. He added, "A few weeks can represent a large portion of the remaining life in these patients, and RFA may be able to give them the best quality of life possible in the time they have left." RFA is a minimally invasive treatment that uses radio frequency waves to create heat that kills tumour cells and destroys nerve fibres, to reduce or stop transmission of pain signals to the brain. In this study, the treatment was used on painful metastatic bone lesions, and was followed up with a cement injection to help stabilise the bone. The cement helped prevent fractures that are known to result following other treatments, such as radiation. Researchers enrolled 218 cancer patients at 15 sites around the world between October 2017 and February 2020. Patients completed questionnaires to measure their quality of life and pain levels prior to the procedure, three days after, and then intermittently through the one-year mark. Researchers used both the five-level EurolQol scale and the European Organization for Research and Treatment of Cancer Quality of Life (EORTC) measurement. Significant improvements were seen in 59 subjects who completed the EurolQol at 12 months, and similar improvements were seen for 14 patients who completed the 12-month EORTC Qol. Because of the palliative nature of the treatment, many patients were unable to be surveyed through the entire 12-month milestone. "What set our results apart from prior research is the sheer speed and durability of this treatment," said Levy, "As a result, we believe this treatment should be available to more patients with metastatic cancer earlier in their treatment path." The research focused on lytic bone metastases, a common type of bone tumour found in many cancer patients. This makes the treatment an option for a wide range of cancer patients. Predominant initial cancers in this study were breast, lung, and kidney.
